Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D R Parkinson
Randomized Comparison of Doxorubicin Alone Versus Ifosfamide Plus Doxorubicin or Mitomycin, Doxorubicin, and Cisplatin Against Advanced Soft Tissue Sarcomas.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma
New England Journal of Medicine
Medicine
Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Systemic Complications of the Bidirectional Intraoperative Chemotherapy With Intravenous Ifosfamide and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Using Cisplatin Plus Doxorubicin
Pleura and Peritoneum
Internal Medicine
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.
Research in Oncology
Sequential Methotrexate and 5-Fluorouracil, Doxorubicin, and Cisplatin for Advanced Urothelial Cancer
Japanese Journal of Urology
Urology
Doxorubicin and 5-Fluorouracil Versus Doxorubicin and Oral Ftorafur in the Treatment of Advanced Gastric Cancer—a Phase II and III Trial
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
High-Dose Epirubicin Is Not an Alternative to Standard-Dose Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. A Study of the EORTC Soft Tissue and Bone Sarcoma Group
British Journal of Cancer
Cancer Research
Oncology
Safety and Efficacy of Combination Therapy With Apatinib and Doxorubicin in Metastatic Soft Tissue Sarcomas: An Observational Study From Multiple Institutions
Cancer Management and Research
Oncology
Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only Against Cisplatin
PLoS ONE
Multidisciplinary
